Mumbai, Sep 13 : Pharma major Granules India said that USFDA has issued Establishment Inspection Report (EIR) for Company's Bonthapally facility located at Hyderabad, Telangana.
This facility was inspected by USFDA in July 2019 and there was one observation during the inspection, company said in a filing with BSE.
Bonthapally facility is one of the world's largest single site Paracetamol API manufacturing plant by volume.
Along with Paracetamol APIs, the Company has established Metformin and Guaifenesin API manufacturing plants in the same facility. (UNI)